AzTrials
AzTrials

Opioid UseNCT03678870

Discharge Opioid Education to Decrease Opioid Use After Cesarean

A study testing Opioid Education Handout in people with Opioid Use, run by Vanderbilt University Medical Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: The number of opioid overdose deaths in the United States has quadrupled in 15 years, a dramatic manifestation of the current opioid abuse epidemic. This rise parallels a sharp increase in the amount of legal prescription opioids dispensed. Read more about this study

Who is it for?
Ages 18 to 45 years, women onlyHealthy volunteers can take part
Conditions the study is for
Opioid Use
What is being tested?
Opioid Education Handout
Could I receive a placebo?
No, everyone receives an active treatment
How many people
196 participants
Where
1 siteUnited States
Study dates
1 Sep 2018to 1 Nov 2019
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Women 18-45 years old
  • Women undergoing cesarean delivery at VUMC

Who cannot join

  • Major post-surgical complications:
  • cesarean hysterectomy, bowel or bladder injury, reoperation, ICU admission, wound infection or separation
  • Chronic opioid use: Taking buprenorphine during pregnancy, taking an opioid for > 7 days during pregnancy.
  • Women who do not speak English

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Sarah Osmundson

    Nashville, Tennessee, 37215

Other trials in United States

About this study

Background: The number of opioid overdose deaths in the United States has quadrupled in 15 years, a dramatic manifestation of the current opioid abuse epidemic. This rise parallels a sharp increase in the amount of legal prescription opioids dispensed. The abundance of prescription opioids available is a primary pathway for opioid abuse and diversion and higher opioid use after surgery has been associated with an increased risk of chronic opioid use. Reducing the amount of opioid used after cesarean delivery may decrease the risk of chronic opioid use and will help towards better estimating and reducing the amount of opioids prescribed at discharge.

Objective: To to compare discharge opioid education to standard care to ascertain whether opioid education reduces opioid use after hospital discharge

Read the detailed description

Background: The number of opioid overdose deaths in the United States has quadrupled in 15 years, a dramatic manifestation of the current opioid abuse epidemic. This rise parallels a sharp increase in the amount of legal prescription opioids dispensed. The abundance of prescription opioids available is a primary pathway for opioid abuse and diversion and higher opioid use after surgery has been associated with an increased risk of chronic opioid use. Reducing the amount of opioid used after cesarean delivery may decrease the risk of chronic opioid use and will help towards better estimating and reducing the amount of opioids prescribed at discharge.

Objective: To to compare discharge opioid education to standard care to ascertain whether opioid education reduces opioid use after hospital discharge

Preliminary Data: Our soon to be published study (Obstetrics \& Gynecology Journal) found that 30% of women used all their opioids after discharge for cesarean delivery because they "were following directions" and not because they had pain.

Enrollment \& Randomization

Enrollment

  • Participants will be approached after their cesarean delivery either in the recovery room or in their private postpartum room
  • Informed written consent will be obtained by a trained research assistant (i.e. medical student) or by the study researchers (Attendings, fellows)
  • After enrollment, participants will be asked to complete Survey 1 either in person or by giving sending them the web link with RedCap

Randomization

  • Enrolled patients will be randomized in a 1:1 ratio using permuted blocks of 6
  • Randomization sequence will be developed through sealed envelope.com
  • Randomization and allocation will be done through RedCap

Study Procedures

  1. Enrollment
  2. Postoperative Day 0-1: Survey 1 through RedCap (takes ~10 minutes)
  3. Randomization education versus usual care
  4. Control = Standard discharge instructions, which list medications prescribed at discharge
  5. Intervention = a single page handout (see attachment) with information about how to use medications for pain after discharge. This handout contains the following instructions
  • Get baseline pain control with ibuprofen
  • Use your opioid prescription only if your pain is very bad
  • Taper your medications
  • Get rid of leftover opioid tablets
  1. At discharge all patients will receive the follow medications using PillsyCaps. These are standard medications given at discharge at our institution
  • Ibuprofen 600mg: 30 tablets
  • Hydrocodone 5mg -acetaminophen 325mg: 30 tablets
  1. Postoperative day 14: All participants will be contacted to complete Survey 2 (Takes ~ 15 minutes
  • Attempts to contact each participant will be done 3 times before they are designated as "lost to follow up"
  • If a participant is still using opioids on postoperative day 14, they should be contacted weekly until they are no longer taking opioids

Primary Outcome Median number of tablets of hydrocodone-acetaminophen used after hospital discharge

Secondary Outcomes:

  • Visual Analog Scale pain score (median)
  • Percentage of patients reporting pain since discharge as worse than expected
  • Percentage of patients obtaining additional prescriptions for pain
  • Percentage of patients with unscheduled visits for pain
  • Mean ibuprofen milligrams used hours 24-47 after cesarean
  • Mean acetaminophen milligrams used hours 24-47 after cesarean
  • Total Morphine Milligram Equivalents (MME) used per hour of inpatient stay

Risks

  • Breach of confidentiality of protected health information

Reporting Adverse Events Any adverse events or unanticipated problems involving risk to participants or others will be reported to the Institutional Review Board and the Vanderbilt University Medical Center (VUMC) privacy office within 7 days of discovery.

Study Withdrawal/discontinuation Participants may withdraw at any time by providing written intent to the Primary Investigator. Participants may be removed from the study if they develop a major surgical complication after their cesarean.

Statistical Considerations

Using prior data, the average opioid MME used per person was 130 MME (SD 90) in the "average use" group. With an alpha of 5% and a beta of 80%, we estimate that 160 total participants are required to show a 30% reduction in opioid used. Assuming a lost to follow up rate of 20%, we plan to enroll 200 women.

Follow-up and Record Retention On average 100 cesareans are performed per month. With a 50% enrollment rate, we anticipate this study will take 4 months to complete

The patient list will be destroyed upon data analysis and publication. Redcap will be archived upon publication.

Conditions
Opioid Use
Being tested
Opioid Education Handout

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Opioid Education HandoutOther

    a single page handout with information about how to use medications for pain after discharge.

Study groups in NCT03678870
Study groupRoleWhat they receive
EducationExperimentalOpioid Education
Receives: Other: Opioid Education Handout
ControlNo interventionstandard discharge instructions, which lists medications prescribed at discharge

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Opioid Use

    Median number of tablets of hydrocodone-acetaminophen used after hospital discharge

    Measured: 6 weeks postpartum

Secondary outcomes (3)
  1. Disposed of Opioids Correctly

    Frequency of women reporting that they either returned their unused opioids to a pharmacy or flushed them down the toilet

    Measured: 6 weeks postpartum

  2. Analgesic Quiz Score

    Median score on an assessment of characteristics of analgesics including side effects, risks, and benefits. Score 1-10 for each question. Higher score is better.

    Measured: 6 weeks postpartum

  3. Additional Prescriptions

    Percentage of patients obtaining additional prescriptions for pain

    Measured: 6 weeks postpartum

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Sep 2018
  2. Study start1 Sep 2018
  3. Primary completion1 Feb 2019
  4. Study completion1 Nov 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
196 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03678870
Sponsor's protocol ID
181190
Status last verified
Feb 2020
First submitted
18 Sep 2018
Last updated
17 Feb 2020
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Schirle LM, Dietrich MS, Lam L, Stone AL, Bruehl S, Osmundson SS. Accuracy of patient-reported versus real-time electronic postoperative opioid use outcomes. Am J Obstet Gynecol MFM. 2021 Jul;3(4):100347. doi: 10.1016/j.ajogmf.2021.100347. Epub 2021 Mar 11. No abstract available.

    PubMed 33716134
  • Lam L, Richardson MG, Zhao Z, Thampy M, Ha L, Osmundson SS. Enhanced discharge counseling to reduce outpatient opioid use after cesarean delivery: a randomized clinical trial. Am J Obstet Gynecol MFM. 2021 Jan;3(1):100286. doi: 10.1016/j.ajogmf.2020.100286. Epub 2020 Dec 3.

    PubMed 33451618

Questions about this trial

What is this clinical trial studying?

A study testing Opioid Education Handout in people with Opioid Use, run by Vanderbilt University Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 5 Feb 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Opioid Use (time frame: 6 weeks postpartum). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03678870, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in